Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"SK Holdings","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Raises $75 Million Series B+ Venture Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"SK Holdings","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Roivant Unveils Targeted Protein Degradation Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by SK Holdings

    Menu

    SK Holdings

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              SK Holdings

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Roivant Unveils Targeted Protein Degradation Platform

              Details:

              Roivant Sciences has secured $200 million to advance its protein degradation ambitions. Armed with the money, Roivant CEO Vivek Ramaswamy plans to use the VantAI platform to spawn multiple new biotech startups.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Recipient: Roivant Sciences

              Deal Size: $200.0 million Upfront Cash: Undisclosed

              Deal Type: Investment December 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SK Holdings

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Harbour BioMed Raises $75 Million Series B+ Venture Capital

              Details:

              More recently, the company has leveraged the power of its antibody discovery platform in select other areas of great unmet medical needs, such as in coronavirus disease (COVID-19).

              Lead Product(s): HBM4003

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Nona Biosciences

              Deal Size: $75.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing March 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY